Plain-English translation of NCT06317467 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This research explores a protein called C1q and antibodies against it to understand why some pregnancies develop serious complications like preeclampsia—a dangerous condition with high blood pressure that can harm both mother and baby. The study compares blood samples from three groups: women with normal pregnancies, women with preeclampsia, and women with autoimmune diseases. By studying these samples, researchers hope to find new ways to prevent or treat preeclampsia and pregnancy loss.
Preeclampsia is a common and serious pregnancy complication that can threaten the health of both mother and baby. Researchers have noticed that women with certain autoimmune conditions are at higher risk, and they believe a specific immune system marker may play a role. This study aims to confirm that connection and potentially open the door to new treatments.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will be placed into one of three groups based on your pregnancy status or health condition. You will be asked to donate blood samples, which will be analyzed for immune system markers. If you are in the normal pregnancy group, you will also need to return to the hospital for a follow-up visit about 40 days after delivery. The study involves no medication or invasive procedures—mainly blood draws and medical information collection.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
Italy